Tg Therapeutics earnings were $447.2M for the trailing 12 months ending Dec 31, 2025, with 1,837.5% growth year over year. The latest TGTX earnings report on Dec 31, 2025 announced Q4 2025 earnings of $23.0M, down 94.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, TGTX reported annual earnings of $447.2M, with 1,812.4% growth.
TGTX past earnings growth
How has TGTX's earnings growth performed historically?
What were Tg Therapeutics's earnings last quarter?
On TGTX's earnings call on Invalid Date, Tg Therapeutics (NASDAQ: TGTX) reported Q4 2025 earnings per share (EPS) of $0.20, up 25% year over year. Total TGTX earnings for the quarter were $23.04 million. In the same quarter last year, Tg Therapeutics's earnings per share (EPS) was $0.16.
As of the last Tg Therapeutics earnings report, Tg Therapeutics is currently profitable. Tg Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2025 was $447.18 million, a 1,812.41% increase year over year.
What was TGTX's earnings growth in the past year?
As of Tg Therapeutics's earnings date in Invalid Date, Tg Therapeutics's earnings has grown 1,837.5% year over year. This is 1,755.09 percentage points higher than the US Biotechnology industry earnings growth rate of 82.41%. TGTX earnings in the past year totalled $447.18 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.